JP2022516099A5 - - Google Patents

Info

Publication number
JP2022516099A5
JP2022516099A5 JP2021537848A JP2021537848A JP2022516099A5 JP 2022516099 A5 JP2022516099 A5 JP 2022516099A5 JP 2021537848 A JP2021537848 A JP 2021537848A JP 2021537848 A JP2021537848 A JP 2021537848A JP 2022516099 A5 JP2022516099 A5 JP 2022516099A5
Authority
JP
Japan
Prior art keywords
weight
pharmaceutical composition
betamethasone
composition according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021537848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516099A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064371 external-priority patent/WO2020139525A1/en
Publication of JP2022516099A publication Critical patent/JP2022516099A/ja
Publication of JP2022516099A5 publication Critical patent/JP2022516099A5/ja
Pending legal-status Critical Current

Links

JP2021537848A 2018-12-27 2019-12-04 眼科用医薬組成物及び癌表面疾患の処置方法 Pending JP2022516099A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785312P 2018-12-27 2018-12-27
US62/785,312 2018-12-27
PCT/US2019/064371 WO2020139525A1 (en) 2018-12-27 2019-12-04 Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease

Publications (2)

Publication Number Publication Date
JP2022516099A JP2022516099A (ja) 2022-02-24
JP2022516099A5 true JP2022516099A5 (enExample) 2022-12-12

Family

ID=71127864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021537848A Pending JP2022516099A (ja) 2018-12-27 2019-12-04 眼科用医薬組成物及び癌表面疾患の処置方法

Country Status (12)

Country Link
US (1) US12070442B2 (enExample)
EP (1) EP3902525A4 (enExample)
JP (1) JP2022516099A (enExample)
KR (1) KR20210141448A (enExample)
CN (1) CN113473970A (enExample)
AU (1) AU2019417161B2 (enExample)
BR (1) BR112021012492A2 (enExample)
CA (1) CA3124945A1 (enExample)
IL (1) IL284344A (enExample)
MX (1) MX2021007709A (enExample)
SG (1) SG11202106967QA (enExample)
WO (1) WO2020139525A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3548091T3 (pl) 2016-11-29 2022-03-28 Oculis SA Otrzymywanie stałych kompleksów cyklodekstryny do dostarczenia czynnego składnika farmaceutycznego do oczu
US11766421B2 (en) * 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
WO2022076398A1 (en) * 2020-10-07 2022-04-14 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
KR20210141448A (ko) 2018-12-27 2021-11-23 서피스 아프샐믹스 인코포레이티드 안구 표면 질환을 치료하기 위한 안과용 약학 조성물 및 방법
DK3993807T3 (da) 2019-07-01 2026-01-19 Oculis Operations Sarl Fremgangsmåde til stabilisering af ph-værden i en vandig sammensætning, der indeholder et lægemiddel
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
JP2025513090A (ja) * 2022-01-24 2025-04-23 サーフィス オフサルミクス,インコーポレイテッド 眼疾患の治療のためのミコフェノール酸及び/又はベタメタゾンの医薬組成物
IL320428A (en) 2022-11-04 2025-06-01 Qlaris Bio Inc Topical ophthalmic administration of cromolyns
EP4616843A1 (en) * 2024-03-13 2025-09-17 Iakov Mirkin Pharmaceutical composition for use in the treatment of ulcerative colitis and in the treatment of interstitial cystitis/bladder pain syndrome

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2503563A1 (fr) 1981-04-09 1982-10-15 Pos Lab Composition pour collyre a base de sulfate de chondroitine a
US4863907A (en) 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use
US4696917A (en) 1985-08-01 1987-09-29 Lindstrom Richard L Irrigation solution
CA2041828A1 (en) 1990-03-05 1992-11-04 Richard L. Lindstrom Viscoelastic solution
DE69231644T2 (de) 1991-04-26 2001-05-23 Fujisawa Pharmaceutical Co., Ltd. Verwendung von makrolid-verbindungen gegen augenerkrankungen
US5518732A (en) 1995-02-14 1996-05-21 Chiron Vision, Inc. Bio-erodible ophthalmic shield
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
WO2000066122A1 (en) 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US6489335B2 (en) 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
EP1142566B1 (fr) * 2000-04-07 2003-10-01 Laboratoire Medidom S.A. Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate
CN1127955C (zh) 2000-07-07 2003-11-19 中山医科大学中山眼科中心 一种眼前段及眼表免疫相关性疾病治疗药物
DE10045343B4 (de) 2000-09-14 2005-05-12 Neuhann, Tobias, Dr.med. Verwendung einer wässrigen Lösung oder Suspension zum Heilen des Hornhautepithels
WO2002049610A2 (en) 2000-12-20 2002-06-27 Alcon, Inc. Ophthalmic irrigating solution adapted for use in lasik surgery
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
GB0404693D0 (en) 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
EP1793836A4 (en) 2004-10-01 2008-09-03 Richard L Lindstrom OPHTHALMIC COMPOSITIONS WITH LUBRICANTS, DETERMINANTS AND GLYCOSAMINOGLYCAN AND METHOD FOR THEIR USE
JP2008520392A (ja) 2004-11-23 2008-06-19 アルコン,インコーポレイティド 天然ポリマーの粘弾性組成物
US20060148686A1 (en) * 2004-12-30 2006-07-06 Bausch & Lomb Incorporated Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
WO2007038687A2 (en) 2005-09-27 2007-04-05 Aciont, Inc. Ocular administration of immunosuppressive agents
DE102005055275A1 (de) 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
EP2035015A4 (en) 2006-05-01 2009-11-11 Riolan Technologies Inc COMPOSITIONS, METHODS AND KITS FOR DRY EYE TREATMENT
WO2008118426A1 (en) 2007-03-26 2008-10-02 Combinatorx, Incorporated Split dose corticosteroid therapy
JP5202986B2 (ja) 2007-09-14 2013-06-05 ロート製薬株式会社 コンタクトレンズ装着液
US9034843B2 (en) 2007-09-14 2015-05-19 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
JP2011505409A (ja) 2007-12-04 2011-02-24 ノバガリ ファーマ エスエー パルミチン酸デキサメタゾンのようなコルチコステロイドプロドラッグを含有する眼障害の治療用の組成物
EP2310008A4 (en) * 2008-07-09 2014-03-05 Aspreva Internat Ltd MYCOPHENOLIC SODIUM ACID SOLUTIONS WITH PH SPECIFIC FOR THE TREATMENT OF OCULAR DISORDERS
US10201548B2 (en) 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US10980818B2 (en) 2009-03-06 2021-04-20 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
JP5595206B2 (ja) 2009-09-30 2014-09-24 ロート製薬株式会社 眼科用液体組成物
EP2308468A1 (en) 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
WO2011059819A2 (en) 2009-10-29 2011-05-19 Colorado State University Research Foundation Polymeric materials including a glycosaminoglycan networked with a polyolefin-containing polymer
FR2962044B1 (fr) 2010-04-21 2013-02-22 Horus Pharma Emulsion lacrymimetique
US9233123B1 (en) 2010-12-07 2016-01-12 Richard L. Lindstrom Use of ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan
SG10201604667YA (en) 2011-04-08 2016-07-28 Nanotheta Co Ltd Pharmaceutical preparation
RU2660585C2 (ru) * 2012-02-10 2018-07-06 Тайвэн Липосом Компани, Лтд. Фармацевтическая композиция для уменьшения осложнений применения стероидных препаратов при лечении офтальмологических заболеваний
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
ITPD20120098A1 (it) 2012-03-30 2013-10-01 Fidia Farmaceutici "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico"
ITMI20120896A1 (it) 2012-05-23 2013-11-24 Bongulielmi Reto Condroitina per uso in medicina
JP2014111587A (ja) 2012-11-06 2014-06-19 Rohto Pharmaceut Co Ltd 眼科用アレルギー予防剤
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
JP6403062B2 (ja) 2012-12-21 2018-10-10 国立大学法人徳島大学 組織修復活性組成物及びその利用
WO2015005458A1 (ja) 2013-07-10 2015-01-15 生化学工業株式会社 グリコサミノグリカン誘導体及びその製造方法
US20150100348A1 (en) 2013-10-08 2015-04-09 Ims Health Incorporated Secure Method for Health Record Transmission to Emergency Service Personnel
EP2979689A1 (en) 2014-07-29 2016-02-03 Sygene Technologies Composition for an eye drop and delivery system therefor
JP2016050181A (ja) * 2014-08-29 2016-04-11 大日本住友製薬株式会社 血管炎治療剤
JP6110037B2 (ja) 2015-01-16 2017-04-05 生化学工業株式会社 コンドロイチン硫酸架橋体、並びにこれを含有する組成物、及び眼疾患処置剤
TWI773641B (zh) 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇(glucocorticoids)之奈米微粒子之水性懸浮液劑
US9789080B2 (en) * 2015-09-04 2017-10-17 Insite Vision Incorporated Ophthalmic formulations of mycophenolic acid
WO2017131130A1 (ja) 2016-01-29 2017-08-03 生化学工業株式会社 コンドロイチン硫酸及びヒアルロン酸を含有する安定化された水性組成物
JP7288289B2 (ja) 2016-11-11 2023-06-07 ロート製薬株式会社 水性眼科組成物
WO2018104950A1 (en) 2016-12-11 2018-06-14 Seanergy Dermatology Ltd. Compositions comprising sulfated polysaccharides
BR112019012568A2 (pt) 2016-12-22 2019-11-26 Novaliq Gmbh composições compreendendo tacrolimus para o tratamento de doenças intraoculares inflamatórias
US20190008920A1 (en) 2017-05-19 2019-01-10 Ocugen, Inc. Ophthalmic compositions and methods of use
WO2018212846A1 (en) * 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use
US20230277557A1 (en) 2017-09-25 2023-09-07 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US20220143075A1 (en) 2017-09-25 2022-05-12 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
JP7104553B2 (ja) 2018-03-30 2022-07-21 ロート製薬株式会社 眼科組成物
JP7417365B2 (ja) 2018-05-09 2024-01-18 ロート製薬株式会社 水性眼科組成物
TW202547536A (zh) 2018-05-09 2025-12-16 日商樂敦製藥股份有限公司 眼科組成物
AU2019384074B2 (en) 2018-11-20 2025-04-10 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
KR20210141448A (ko) 2018-12-27 2021-11-23 서피스 아프샐믹스 인코포레이티드 안구 표면 질환을 치료하기 위한 안과용 약학 조성물 및 방법
JP6866412B2 (ja) 2019-02-28 2021-04-28 株式会社伊勢半 油中水型乳化化粧料
JP7758466B2 (ja) 2019-11-07 2025-10-22 ロート製薬株式会社 眼科組成物
WO2021162529A1 (ko) 2020-02-14 2021-08-19 연세대학교 산학협력단 페놀 유도체가 수식된 콘드로이틴 설페이트 하이드로젤 및 이의 용도
JP2022157707A (ja) 2021-03-31 2022-10-14 ロート製薬株式会社 眼科組成物
WO2022240589A1 (en) 2021-05-12 2022-11-17 Schlumberger Technology Corporation Autonomous inflow control device system and method
JP2025513090A (ja) 2022-01-24 2025-04-23 サーフィス オフサルミクス,インコーポレイテッド 眼疾患の治療のためのミコフェノール酸及び/又はベタメタゾンの医薬組成物

Similar Documents

Publication Publication Date Title
JP2022516099A5 (enExample)
JP6886502B2 (ja) アトロピン含有水性組成物
AU738413B2 (en) Human growth hormone-containing aqueous pharmaceutical composition
JP4153563B2 (ja) 医薬組成物
CN102014920B (zh) 滴眼剂制剂及其应用
JP2023058566A (ja) 安定なペプチド組成物
JP4434486B2 (ja) 医薬組成物
JPH08291065A (ja) 有機アミンを配合したプラノプロフェン点眼液
JP2015028043A (ja) S−アデノシルメチオニンの安定な塩およびその調製のための方法
WO2012013116A1 (zh) 含氨基酸稳定剂的替莫唑胺药物组合物及其制备方法
WO2021049963A1 (en) Pharmaceutical composition of bimatoprost and timolol
US4328213A (en) Stable injectable labetalol formulation
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
JPH10338638A (ja) 損傷皮膚修復用製剤
US5093348A (en) Pharmaceutical composition for topical ophthalmic use having improved local tolerability
JPH1180021A (ja) バンコマイシン注射剤
JPH04261117A (ja) グリチルリチン坐剤
JP2010275259A (ja) 均一、かつ安定なラタノプロスト点眼液剤組成物
US20100016219A1 (en) Ophthalmic compositions containing solubilized cyclosporin
JPH04149132A (ja) ダナゾール水溶液
TW202426032A (zh) 棘白素類似物的藥物組合物及其製備方法
JP2003300908A (ja) 安定なカルシトニン注射用製剤
CN112007031A (zh) 眼用制剂
JPH08208598A (ja) プロスタグランジン類組成物
TW201302755A (zh) 含胺基酸穩定劑的替莫唑胺醫藥組成物及其製備方法